Сучасні аспекти лікування гіпертонічної хвороби, поєднаної з ішемічною хворобою серця
DOI:
https://doi.org/10.37987/1997-9894.2020.1(237).214171Ключові слова:
ішемічна хвороба серця, гіпертонічна хвороба, антигіпертензивні засоби, цільовий артеріальний тиск, феномен J-кривої, несприятливі серцево-судинні події, кінцеві точкиАнотація
Ішемічна хвороба серця (ІХС) залишається головною причиною смертності та захворюваності у світі, до категорії особливо високого ризику належать пацієнти з гіпертонічною хворобою (ГХ). Як відомо, високий артеріальний тиск (АТ) у пацієнтів – один із найважливіших факторів серцево-судинного ризику, який можна модифікувати. Досягнення оптимальних рівнів АТ у цій популяції пацієнтів приводить до зни-ження ризику небажаних подій, однак надмірне зниження АТ може призводити до зниження міокардіальної та церебральної перфузії, існує залежність у пацієнтів з крайніми цифрами артеріального тиску (АТ) у вигляді J-кривої. У статті проведено аналіз даних досліджень пацієнтів з ІХС та ГХ залежно від різних цільових рівнів зниження АТ у світлі нових рекомендацій на тлі медикаментозної терапії.
Посилання
National Center for Health Statistics (US). Health, United States, 2015: with special feature on racial and ethnic health disparities. – Hyattsville, MD: National Center for Health Statistics (US), 2016, 5. – Report no.: 2016–1232.
World Health Organization (WHO). Causes of death 2008: data sources and methods. Department of Health Statistics and Informatics, World Health Organization. – Geneva, 2011. – Р. 1–28.
Heart disease and stroke statistics–2017 update: a report from the American Heart Association / E. J. Benjamin, M. J. Blaha, S. E. Chiuve [et al.] // Circulation. – 2017. – No. 135 (10). – Р. e146–е603.
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies / S. Lewington, R. Clarke, N. Qizilbash [et al.] // Lancet. – 2002. – No. 360. – Р. 1903–1913.
Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) / B. R. Davis, J. A. Cutler, D. J. Gordon [et al.] // Am. J. Hypertens. – 1996. – No. 9 (4). – Р. 342–360.
Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease / J. A. N. Dorresteijn, Y. van der Graaf, W. Spiering [et al.] // Hypertension. – 2012. – No. 59. – Р. 14–21.
Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group // JAMA. – 1979. – No. 242. – Р. 2562–2571.
Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial- HOT Study Group / L. Hansson, A. Zanchetti, S. G. Carruthers [et al.] // Lancet. – 1998. – No. 351. – Р. 1755–1762.
Long-term mortality in hypertensive patients with coronary artery disease / I. Y. Elgendy, A. A. Bavry, Y. Gong [et al.] // Hypertension. – 2016. – No. 68 (5). –Р. 1110–1114.
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? / F. H. Messerli, G. Mancia, C. R. Conti [et al.] // Ann. Intern. Med. – 2006. – No. 144 (12). – Р. 884–893.
Diastolic blood pressure and mortality in the elderly with cardiovascular disease / A. D. Protogerou, M. E. Safar, P. Iaria [et al.] // Hypertension. – 2007. – No. 50 (1). – Р. 172–180.
Cruickshank J. M. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction / J. M. Cruickshank // BMJ. – 1988. – No. 297 (6658). – Р. 1227–1230.
Secondary Manifestations of Arterial Disease Study Group. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited / J. A. N. Dorresteijn, Y. van der Graaf, W. Spiering [et al.] // Hypertension. – 2012. – No. 59 (1). – Р. 14–21.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 //BMJ. – 1998. – No. 317 (7160). – Р. 703–713.
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis / X. Xie, E. Atkins, J. Lv [et al.] //Lancet. – 2016. – No. 387 (10017). – Р. 435–443.
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial / K. L. Margolis, P. J. O’Connor, T. M. Morgan [et al.] // Diabetes Care. – 2014. – No. 37 (6). – Р. 1721–1728.
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines / P. K. Whelton, R. M. Carey, W. S. Aronow [et al.] // J. Am. Coll. Cardiol. – 2018. – No. 71 (19). –Р. e127–e248.
Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension / C. Rosendorff, D. T. Lackland, M. Allison [et al.] // Hypertension. – 2015. – No. 65 (6). – Р. 1372–1407.
ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension / B. Williams, G. Mancia, W. Spiering [et al.] // European. Heart. Journal. – 2018. – No. 39 (33). – Р. 3021–104.
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis / D. Ettehad, C. A. Emdin, A. Kiran [et al.] //Lancet. – 2016. – No. 387. – Р. 957–967.
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis / D. Ettehad, C.A. Emdin, A. Kiran [et al.] //Lancet. – 2016. – No. 387. – Р. 957–967
Law M. R. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies / M. R. Law, J. K. Morris, N. J. Wald // BMJ. – 2009. – No. 338. – Р. b1665.
Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and metaregression analyses of randomized trials / C. Thomopoulos, G. Parati, A. Zanchetti // J. Hypertens. – 2014. – No. 32. – Р. 2285–2295.
Achieved blood pressure and outcomes in the secondary prevention of small subcortical strokes trial / M. C. Odden, L. A. McClure, B. P. Sawaya [et al.] //Hypertension. – 2016. – No. 67. – Р. 63–69.
Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension / C. Rosendorff, D. T. Lackland, M. Allison [et al.] // Hypertension. – 2015. – No. 65 (6). – Р. 1372–1407.
Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction / S.M. Wallace, C. M. McEniery, K. M. Mäki-Petäjä [et al.] //Hypertension. – 2007. – No. 50 (1). – Р. 228–233.
Influence of increased heart rate and aortic pressure on resting indices of functional coronary stenosis severity / L. Casadonte, B. J. Verhoeff, J. J. Piek [et al.] // Basic Res Cardiol. – 2017. – No. 112 (6). – Р. 61.
Angiotensin inhibition and coronary autoregulation in a canine model of LV hypertrophy / J. R. Rouleau, D. Simard, A. Blouin [et al.] // Basic Res Cardiol. – 2002. – No. 97 (5). – Р. 384–391.
Hoffman J.I. Heterogeneity of myocardial blood flow / J. I. Hoffman // Basic. Res. Cardiol. – 1995. – No. 90 (2). – Р. 103–111.
Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study / T. E. Craven, J. E. Ryu, M. A. Espeland [et al.] // Circulation. – 1990. – No. 82 (4). – Р. 1230–1242.
Prevalence of conventional risk factors in patients with coronary heart disease / U. N. Khot, M. B. Khot, C. T. Bajzer [et al.] // JAMA. – 2003. – No. 290 (7). – Р. 898–904.
Hyman D. J. Characteristics of patients with uncontrolled hypertension in the United States / D. J. Hyman, V. N. Pavlik // N. Engl. J. Med. – 2001. – No. 345. –Р. 479–486.
Potential US population impact of the 2017 ACC/AHA High Blood Pressure Guideline / P. Muntner, R. M. Carey, S. Gidding [et al.] // J. Am. Coll. Cardiol. –2018. – No. 71 (2). – Р. 109–118.
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy / M. A. Weber, S. Julius, S. E. Kjeldsen [et al.] J. Hypertens. – 2012. – No. 30 (11). – Р. 2213–2222.
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension / S. M. Smith, Y. Gong, E. Handberg [et al.] // J. Hypertens. – 2014. – No. 32 (3). – Р. 635.
Morgan T. O. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension / T. O. Morgan, A. I. Anderson, R. J. MacInnis // Am. J. Hypertens. – 2001. – No. 14 (3). – Р. 241–247.
Messerli F. H. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? / F. H. Messerli, E. Grossman, U. Goldbourt //JAMA. – 1998. – No. 279. – Р. 1903–1907.
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduc tion in Hypertension study (LIFE): a randomised trial against atenolol / B. Dahlöf, R. B. Deve reux, S. E. Kjeldsen [et al.] // Lancet. – 2002. – No. 359 (9311). – Р. 995–1003.
Beta-blockers for hypertension / C. S. Wiysonge, H. A. Bradley, J. Volmink [et al.] //Cochrane Database Syst. Rev. – 2012. – No. 11.
Acute β-adrenergic blockade increases aortic wave reflection in young men and women: differing mechanisms between sexes / D. P. Casey, T. B. Curry, M. J. Joyner [et al.] // Hypertension. – 2012. – No. 59 (1). – Р. 145–150.
Peart S. MRC trial of treatment of mild hypertension / S. Peart, G. Greenberg //BMJ (Clinical research ed.). – 1985. – No. 291 (6491). – Р. 347.
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) / ALLHAT Collaborative Research Group // JAMA. – 2002. – No. 288 (23). – Р. 2981–2997.
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial / M. A. Pfeffer, E. Braunwald, L. A. Moyé [et al.] // New Engl J Med. – 1992. – No. 327 (10). – Р. 669–677.
European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. – 2003. – No. 362 (9386). – Р. 782–788.
Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients // N. Engl. J. Med. – 2000. – No. 2000 (342). – Р. 154–160.
PEACE Trial Investigators. Angiotensin-converting–enzyme inhibition in stable coronary artery disease // N. Engl. J. Med. – 2004. – No. 2004 (351). – Р. 2058–2068.
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both / M. A. Pfeffer, J. J. McMurray, E. J. Velazquez [et al.] // N. Engl. J. Med. – 2003. – No. 349 (20). – Р. 1893–1906.
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial / J. F. Mann, R. E. Schmieder, M. McQueen [et al.] // Lancet. – 2008. – No. 372 (9638). – Р. 547–553.
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial / S. Julius, S. E. Kjeldsen, M. Weber [et al.] // Lancet. – 2004. – No. 363 (9426). – Р. 2022–2031.
Law M. R. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies / M. R. Law, J. K. Morris, N. J. Wald // BMJ. – 2009. – No. 338. – Р. b1665.
A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial / C. J. Pepine, E. M. Handberg, R. M. Cooper-DeHoff [et al.] // JAMA. – 2003. – No. 290 (21). – Р. 2805–2816.
Law M. R. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies / M. R. Law, J. K. Morris, N. J. Wald // BMJ. – 2009. – No. 338. – Р. b1665.
VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy / L. F. Fried, N. Emanuele, J. H. Zhang [et al.] // N. Engl. J. Med. – 2013. – No. 369. – Р. 1892–1903.
A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial / C. J. Pepine, E. M. Handberg, R. M. Cooper-DeHoff [et al.] // JAMA. – 2003. – No. 290 (21). – Р. 2805–2816.
Law M. R. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies / M. R. Law, J. K. Morris, N. J. Wald // BMJ. – 2009. – No. 338. – Р. b1665.
Особливості ведення пацієнтів з артеріальною гіпертензією і коморбідними станами сімейними лікарями (з урахуванням Європейських рекомендацій 2018 року) : методичні рекомендації / М. М. Долженко, І. В. Давидова, В. А. Несукай та співавт. – Київ, 2018.
